Evidence map›Paper›PMID 33196458›Full record

ArticleAging2020

Drug-selected population in melanoma A2058 cells as melanoma stem-like cells retained angiogenic features - the potential roles of heparan-sulfate binding ANGPTL4 protein.

Chia-Yu Shih, Yu-Che Cheng, ChiaoHui Hsieh, TingTing Tseng, ShihSheng Jiang, Shao-Chen Lee

Open access · greenAbstract read
In one paragraph

Article in Aging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Marine drugs · 2026
    Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Chia-Yu ShihSchool of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei, Taiwan.
Yu-Che ChengSchool of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei, Taiwan.
ChiaoHui HsiehSchool of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei, Taiwan.
TingTing TsengSchool of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei, Taiwan.
ShihSheng JiangNational Institute of Cancer Research, National Health Research Institutes, Miaoli, Taiwan.
Shao-Chen LeeSchool of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei, Taiwan.
Fu Jen Catholic University · TWCathay General Hospital · TWNational Health Research Institutes · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant cancer may contain highly heterogeneous populations of cells, including stem-like cells which were resistant to chemotherapy agents, radiation, mechanical stress, and immune surveillance. The characterization of these specific subpopulations might be critical to develop novel strategy to remove malignant tumors. We selected and enriched small population of human melanoma A2058 cells by repetitive selection cycles (selection, restoration, and amplification). These subpopulation of melanoma cells persisted the characteristics of slower cell proliferation, enhanced drug-resistance, elevated percentage of side population as analyzed by Hoechst33342 exclusion,

Indexed as

Drug Resistance, NeoplasmAngiopoietin-Like Protein 4Cell Line, TumorHeparan Sulfate ProteoglycansHumansMelanomaNeoplastic Stem CellsNeovascularization, PathologicProtein BindingAngiopoietin-Like Protein 4ANGPTL4 protein, humanHeparan Sulfate Proteoglycansangiopoietin-like 4 proteindrug resistancemelanoma stem-like cells

Identifiers

PMID33196458
PMCPMC7746371
OpenAlexW3099467361

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.